Yun-Bae Kim | Medicine and Health Sciences | Best Researcher Award

Published on by Research Hypothesis

Prof. Yun-Bae Kim | Medicine and Health Sciences | Best Researcher Award

Prof. Yun-Bae Kim | Medicine and Health Sciences | Best Researcher Award | Professor | Chungbuk National University | South Korea

Prof. Yun-Bae Kim, a distinguished professor at the Department of Toxicology, College of Veterinary Medicine, Chungbuk National University, Republic of Korea, is an eminent scholar in the fields of toxicology, neurobiology, and regenerative medicine. Holding both a Doctor of Veterinary Medicine (D.V.M.) and a Ph.D. in Veterinary Medicine from Seoul National University, Prof. Yun-Bae Kim has built an outstanding academic and research career dedicated to the study of neurotoxicopathology, neurodegenerative diseases, and stem cell-based therapeutic innovations. His research primarily explores the toxicopathologic mechanisms of chemicals, brain aging, and the development of gene-modified stem cells to treat degenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and cerebral palsy. With over 370 peer-reviewed publications and patents indexed in Scopus, PubMed, and other global databases, Prof. Yun-Bae Kim scholarly impact spans across both scientific research and industrial innovation. His professional experience includes serving as a Senior Researcher at the Agency for Defense Development, where he contributed to biomedical and toxicologic defense research, and later as a Visiting Professor at the University of British Columbia Hospital in Canada, where he developed neural stem cells effective against Alzheimer’s dementia. Prof. Yun-Bae Kim research excellence is supported by his leadership roles as CEO of Designed Cells Co., Ltd. in Korea, Vice-Chair of Qingdao Sinder Designed Stem Cells Co., Ltd. in China, Co-Chair of Designed Cells Europe D.O.O. in Croatia, and Chief Scientific Officer of ThanEver Inc. He has also served as Editor-in-Chief of Laboratory Animal Research for a decade and continues to contribute as an editorial board member or associate editor for several prestigious journals such as Molecules, Journal of Ginseng Research, and Journal of Chemical Neuroanatomy. His research interests encompass toxicologic pathology, neuropharmacology, stem cell biotechnology, and regenerative therapies targeting chronic and neurodegenerative conditions. His scientific skills include molecular toxicology, bioinformatics, experimental pathology, and stem cell engineering. Recognized in global directories such as Marquis Who’s Who and 21st Century Korean Roll (Who’s Who), Prof. Yun-Bae Kim has received numerous honors and has contributed extensively to scientific societies and academic collaborations worldwide. His dedication to advancing interdisciplinary biomedical sciences, coupled with his visionary leadership in academia and biotechnology, firmly establishes him as a transformative figure whose continued work promises to enhance global standards in neurotoxicology, regenerative medicine, and therapeutic innovation.

Profile:  Google scholar | Scopus

Featured Publications

  1. Kim, Y.-B., et al. (2024). BVN008, Diphtheria-tetanus-acellular pertussis combined vaccine has no effects on fertility and prenatal and postnatal developmental toxicity in female Sprague-Dawley rats. Reproductive Toxicology, 126, 108587. (1 citation)

  2. Kim, Y.-B., et al. (2024). The Role of Prolactin in Amniotic Membrane Regeneration: Therapeutic Potential for Premature Rupture of Membranes. Endocrinology.

  3. Kim, Y.-B., et al. (2023). Repeated Intravenous Administration of Human Neural Stem Cells Producing Choline Acetyltransferase Exerts Anti-Aging Effects in Male F344 Rats. Cells, 12(5). (2 citations)

  4. Kim, Y.-B., et al. (2023). An Exosome-Rich Conditioned Medium from Human Amniotic Membrane Stem Cells Facilitates Wound Healing via Increased Reepithelization, Collagen Synthesis, and Angiogenesis. Cells, 12(4). (12 citations)

  5. Kim, Y.-B., et al. (2023). Preventive Effects of Exosome-Rich Conditioned Medium From Amniotic Membrane-Derived Mesenchymal Stem Cells for Diabetic Retinopathy in Rats. Translational Vision Science & Technology, 12(6). (10 citations)

  6. Kim, Y.-B., et al. (2023). Effectiveness of Combinational Treatments for Alzheimer’s Disease with Human Neural Stem Cells and Microglial Cells Over-Expressing Functional Genes. International Journal of Molecular Sciences, 24(9). (6 citations)

  7. Kim, Y.-B., et al. (2023). Antioxidative and Anti-Inflammatory Activities of Rosebud Extracts of Newly Crossbred Roses. Nutrients, 15(10). (3 citations).

 

Denise Faustman | Medicine and Health Sciences | Best Researcher Award

Published on by Research Hypothesis

Dr. Denise Faustman | Medicine and Health Sciences | Best Researcher Award

Direcotr of immunobiology laboratory | washington university school of medicine | United States

Dr. Denise Faustman is a physician-scientist whose career exquisitely bridges clinical medicine, immunology, and translational research. She earned her Ph.D. in Molecular and Cellular Biology along with her M.D. in Medicine from Washington University School of Medicine, and she holds a bachelor’s degree in Zoology & Chemistry from the University of Michigan. Over her professional journey, Dr. Faustman has held roles such as Director of the Immunobiology Laboratory at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School, and she continues to lead efforts in immunotherapy, autoimmunity, and metabolic modulation. Her research interests center on autoimmune disease mechanisms, autoreactive T cells, the immunoregulatory role of TNF/TNFR2, use of Bacillus Calmette–Guérin (BCG) vaccine in type 1 diabetes, epigenetic modulation of immune cells, and the intersection of immunometabolism and regenerative therapies. Her technical and methodological skills span immunology assays (flow cytometry, T-cell functional assays, cytokine profiling), epigenetic and methylation analyses, transcriptomics, metabolomics, clinical trial design, and translational biomarker development. In her career she has authored 115 documents, has accrued 5,972 citations, and holds an h-index of 42, attesting to her sustained academic influence. Professionally, Dr. Faustman has led multiple NIH-funded and translational projects, engaged in global advisory committees (including in immunology, diabetes, and regulatory policy), and established collaborations across institutions in North America and Europe. She has served on scientific advisory boards, chaired expert panels, participated in FDA and NIH review committees, and mentored many early-career scientists. Her honors include recognition for contributions to autoimmune disease research, invitations as plenary or keynote speaker at international conferences, and appointments to leadership roles in professional societies and advisory bodies. In summary, Dr. Denise Faustman combines deep scientific insight, rigorous methodological skill, leadership in translational immunology, and a track record of high-impact publications to make significant contributions both to fundamental immunology and to treatments for type 1 diabetes and other autoimmune diseases. She is well positioned to continue driving innovation in immunotherapy, to mentor the next generation of biomedical scientists, and to lead large-scale international collaborative projects that translate immunological discoveries into patient benefit.

Profile: ORCID | Scopus

Featured Publications

  1. Faustman, D. L. (2001). Reversal of established autoimmune diabetes by restoration of endogenous beta cell function. Journal of Clinical Investigation.

  2. Kodama, S., Kuhtreiber, W., Fujimura, S., Dale, E. A., & Faustman, D. L. (2003). Islet regeneration during the reversal of autoimmune diabetes in NOD mice. Science.

  3. Kühtreiber, W. M., Tran, L., Kim, T., Dybala, M., Nguyen, B., Plager, S., Huang, D., Janes, S., Defusco, A., Baum, D., Zheng, H., & Faustman, D. L. (2018). Long-term reduction in hyperglycemia in advanced type 1 diabetes: the value of induced aerobic glycolysis with BCG vaccinations.

  4. Kuhtreiber, W. M., et al. (2023). BCG clinical trial programs in advanced type 1 diabetes.

  5. Faustman, D. L., Davis, M. (2013). TNF receptor 2 and disease: autoimmunity and regenerative medicine.